Attached files

file filename
EX-99.1 - PRESS RELEASE DATED DECEMBER 17, 2015 - Mawson Infrastructure Group Inc.f8k121715ex99i_ophthalixinc.htm

 


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported)   December 17, 2015

 

OphthaliX Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   000-52545   88-0445167
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

10 Bareket Street, Petach Tikva, Israel   4951778
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code:  +(972) 3-924 1114

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  Written communications pursuant to Rule 425 under the Securities Act
     
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
     
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

 

  

 

 

 

Item 8.01         Other Events.

 

On December 17, 2015, OphthaliX, Inc. issued a press release announcing that the Japan Patent Office has granted a patent for CF101 for the reduction of intraocular pressure in a patent titled, "A3 adenosine receptor agonists for the reduction of intraocular pressure".

 

Item 9.01         Financial Statements and Exhibits.

 

(d)  Exhibits

 

Exhibit

No.

  Description
99.1   Press Release dated December 17, 2015

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  OphthaliX Inc.
     
Date:  December 17, 2015 By /s/ Pnina Fishman
    Pnina Fishman, Interim CEO

 

 

 

3